Flumazenil in cirrhotic patients in hepatic coma: A randomized double‐blind placebo‐controlled crossover trial

Hepatology

Volumn 19, Issue 1, 1994, Pages 32-37

  Pomier‐Layrargues, Gilles ^a   Giguere J F ^b   Lavoie, J ^b   Perney, P ^a   Gagnon, S ^b   D'Amour, M ^b   Wells, J ^c   Butterworth, Roger F ^b  

^a UNIVERSITY OF MONTREAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c Ontario Centre of Forensic Sciences   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE; BENZODIAZEPINE RECEPTOR; DIAZEPAM; FLUMAZENIL; LACTULOSE; LORAZEPAM; NORDAZEPAM; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; ELECTROENCEPHALOGRAPHY; FEMALE; HEPATIC COMA; HEPATIC ENCEPHALOPATHY; HUMAN; INJURY SCALE; INTRAVENOUS DRUG ADMINISTRATION; LIVER CIRRHOSIS; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; AGED; BENZODIAZEPINES; DOUBLE-BLIND METHOD; FEMALE; FLUMAZENIL; HEPATIC ENCEPHALOPATHY; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTORS, GABA-A;

EID: 0027952648     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.1840190107     Document Type: Article

References (35)

1. Could an endogenous benzodiazepine ligand contribute to hepatic encephalopathy
2. The pathogenesis and treatment of hepatic encephalopathy: evidence for the involvement of benzodiazepine receptors ligands
3. A benzodiazepine antagonist does not alter the course of hepatic encephalopathy or neural gamma‐aminobutyric (GABA) binding
4. Amelioration of hepatic encephalopathy by pharmacologic antagonism of the GABA‐benzodiazepine receptor complex in a rabbit model of fulminant hepatic failure
5. Flumazenil in the treatment of portal systemic encephalopathy
6. Methods of assessing hepatic encephalopathy
7. Biomedical applications of selected ion monitoring
8. Quantitation of the benzodiazepine antagonist flumazenil in human plasma by gas chromatography‐mass spectrometry
9. Reversal of hepatic coma by benzodiazepine antagonist (RO 15–1788)
10. Reversal of hepatic coma by benzodiazepine antagonist (RO 15–1788)
11. Effects of the benzodiazepine receptor antagonist flumazenil in hepatic encephalopathy in humans
12. Treatment of hepatic encephalopathy with the benzodiazepine antagonist flumazenil: a pilot study
13. Reversal of hepatic coma with flumazenil with improvement in visual evoked potentials
14. Étude électroencéphalographique de l'effet d'un antagoniste des benzodiazepines dans l'encéphalopathie hépatique
15. Improvement of hepatic encephalopathy treated with flumazenil
16. RO 15–1788 and hepatic failure
17. Effects immédiats sur le degré clinique et électroencéphalographique de l'encéphalopathie hépatique chez le cirrhotique [Abstract]
18. Flumazenil therapy for hepatic encephalopathy: a double‐blind cross‐over study [Abstract]
19. Persisting benzodiazepine metabolites responsible for the reaction to the benzodiazepine antagonist flumazenil in patients with hepatic encephalopathy
20. Flumazenil and hepatic encephalopathy
21. Flumazenil: a preliminary review of the benzodiazepine antagonist properties, intrinsic activity and therapeutic use
22. Benzodiazepine intoxication treated with flumazenil (anexate, RO 15–1788)
23. Pharmacokinetics of benzodiazepine antagonist RO 15–1788 in cirrhotic patients with moderate or severe liver dysfunction
24. Gamma‐aminobutyric acid and benzodiazepine receptors in an animal model of fulminant hepatic failure
25. Supersensitivity of benzodiazepine receptors in hepatic encephalopathy due to fulminant hepatic failure in the rat: reversal by a benzodiazepine antagonist
26. Plasma GABA, GABA‐like activity and the brain GABA‐benzodiazepine receptor complex in rats with chronic hepatic encephalopathy
27. 3H muscimol (GABA‐A) binding sites and of central benzodiazepine receptors are unchanged in autopsied brain tissue from cirrhotic patients with hepatic encephalopathy
28. Endogenous benzodiazepine receptors ligands in human and animal hepatic encephalopathy
29. “Endogenous” benzodiazepine activity in body fluids of patients with hepatic encephalopathy
30. Endogenous benzodiazepines in hepatic encephalopathy
31. Elevated brain concentrations of 1–4 benzodiazepines in fulminant hepatic failure
32. Intrinsic actions of the benzodiazepine receptor antagonist RO 15–1788